{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T08:16:04Z","timestamp":1787991364350,"version":"build-2784847793"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Melorheostosis is a rare disease where excessive bone overgrowth and exostoses cause deformity and pain. Somatic mutations of MAP2K1 result in hyperactivation of the ERK pathway in osteoblasts and increase in vitro mineralization. Currently, there is no effective treatment. Because melorheostosis-derived osteoblasts show increased expression of cell cycle proliferation-related molecules compared to controls, we hypothesized that rapid progression through the cell cycle contributes to the bony overgrowth. We used an induced pluripotent stem cell (iPSCs) model from unaffected and affected regions of patient skin fibroblasts. We then differentiated iPSCs into induced mesenchymal stromal cells (iMSCs), and then into osteoblasts. Using propidium iodide (PI) mediated cell cycle assay with flow cytometry, we recorded that affected iMSCs (and primary patient osteoblasts) have a higher proportion of proliferative cells than unaffected. We noticed that affected osteoblasts and iMSCs have elevated the expression of phospho-Rb\u2014a crucial molecule for G1 to S phase transition. Immunofluorescence confirmed a significantly higher cell proliferation marker Ki-67 index in affected iMSCs. EdU incorporation assays validated higher percentage of S phase cells in affected populations. We applied the FDA-approved CDK4 inhibitor palbociclib to iMSCs and primary osteoblasts and found significant reduction of phospho-Rb. Palbociclib treated iMSCs and osteoblasts displayed elevated G0\/G1 peak on flow cytometry and lowered EdU incorporation, thus confirming blockade of cell cycle progression by limiting S phase entry. Interestingly, palbociclib treatment for an initial 5\u00a0d of total 21\u00a0d of osteogenic stimulation restricts mineralization in affected cells to a greater extent than unaffected. This suggests that increased proliferation is contributing to the bone growth phenotype in patients. Thus, our data suggest that targeting cell cycle machinery can be a potential therapeutic approach for melorheostosis patients.<\/jats:p>","DOI":"10.1093\/jbmr\/zjaf186","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T12:56:37Z","timestamp":1765284997000},"page":"998-1011","source":"Crossref","is-referenced-by-count":1,"title":["CDK4 inhibition reduces proliferation and mineralization in MAP2K1+ melorheostosis: opening a pathway to treatment"],"prefix":"10.1093","volume":"41","author":[{"given":"Jyotirindra","family":"Maity","sequence":"first","affiliation":[{"name":"Clinical and Investigative Orthopedics Surgery Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health , Bethesda, MD 20892 ,","place":["United States"]},{"name":"Department of Biotechnology, Sharda School of Bioscience and Technology, Sharda University , Greater Noida, Uttar Pradesh 201310 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gourinandan","family":"Saravanan","sequence":"additional","affiliation":[{"name":"Clinical and Investigative Orthopedics Surgery Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health , Bethesda, MD 20892 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Navid","sequence":"additional","affiliation":[{"name":"Pediatric Translational Research Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health , Bethesda, MD 20892 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarthak","family":"Gupta","sequence":"additional","affiliation":[{"name":"Pathway Driven Therapeutics in Lupus and Related Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health , Bethesda, MD 20892 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Colbert","sequence":"additional","affiliation":[{"name":"Pediatric Translational Research Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health , Bethesda, MD 20892 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4041-3320","authenticated-orcid":false,"given":"Timothy","family":"Bhattacharyya","sequence":"additional","affiliation":[{"name":"Clinical and Investigative Orthopedics Surgery Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health , Bethesda, MD 20892 ,","place":["United States"]},{"name":"Department of Biotechnology, Sharda School of Bioscience and Technology, Sharda University , Greater Noida, Uttar Pradesh 201310 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"issue":"3","key":"2026082903274097600_ref1","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1007\/s003300000562","article-title":"Melorheostosis: a review of 23 cases","volume":"11","author":"Freyschmidt","year":"2001","journal-title":"Eur Radiol"},{"issue":"1","key":"2026082903274097600_ref2","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s41467-018-03720-z","article-title":"Somatic activating mutations in MAP2K1 cause melorheostosis","volume":"9","author":"Kang","year":"2018","journal-title":"Nat Commun"},{"issue":"1","key":"2026082903274097600_ref3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/jbmr.3577","article-title":"Distinct clinical and pathological features of melorheostosis associated with somatic MAP2K1 mutations","volume":"34","author":"Jha","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2026082903274097600_ref4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3928\/0147-7447-20010301-20","article-title":"Histopathological characterization of melorheostosis","volume":"24","author":"Hoshi","year":"2001","journal-title":"Orthopedics."},{"issue":"11","key":"2026082903274097600_ref5","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1097\/PAS.0000000000001310","article-title":"Melorheostosis: a clinical, pathologic, and radiologic case series","volume":"43","author":"Fick","year":"2019","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"2026082903274097600_ref6","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.2106\/00004623-198769080-00019","article-title":"Osteosarcoma arising in a melorheostotic femur. A case report","volume":"69","author":"Bostman","year":"1987","journal-title":"J Bone Joint Surg Am"},{"issue":"2","key":"2026082903274097600_ref7","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziae163","article-title":"Unraveling melorheostosis: insights into clinical features, diagnosis, and treatment","volume":"9","author":"Bhattacharyya","year":"2025","journal-title":"JBMR Plus"},{"issue":"12","key":"2026082903274097600_ref8","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1002\/jbmr.4915","article-title":"VEGF secretion drives bone formation in classical MAP2K1+ Melorheostosis","volume":"38","author":"Allbritton-King","year":"2023","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2026082903274097600_ref9","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.bbamcr.2006.10.005","article-title":"The MEK\/ERK cascade: from signaling specificity to diverse functions","volume":"1773","author":"Shaul","year":"2007","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"2026082903274097600_ref10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.phrs.2012.04.005","article-title":"ERK1\/2 MAP kinases: structure, function, and regulation","volume":"66","author":"Roskoski","year":"2012","journal-title":"Pharmacol Res"},{"issue":"8","key":"2026082903274097600_ref11","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1158\/1078-0432.CCR-14-2124","article-title":"MAP2K1 (MEK1) mutations define a distinct subset of lung adenocarcinoma associated with smoking","volume":"21","author":"Arcila","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2026082903274097600_ref12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1158\/1541-7786.MCR-20-0687","article-title":"The MEK\/ERK network as a therapeutic target in human cancer","volume":"19","author":"Barbosa","year":"2021","journal-title":"Mol Cancer Res"},{"issue":"22","key":"2026082903274097600_ref13","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1038\/sj.onc.1210414","article-title":"The ERK1\/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition","volume":"26","author":"Meloche","year":"2007","journal-title":"Oncogene."},{"issue":"3","key":"2026082903274097600_ref14","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1073\/pnas.95.3.1091","article-title":"Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1)","volume":"95","author":"Cheng","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"issue":"23","key":"2026082903274097600_ref15","doi-asserted-by":"publisher","first-page":"24899","DOI":"10.1074\/jbc.M311622200","article-title":"Mitogen-induced rapid phosphorylation of serine 795 of the retinoblastoma gene product in vascular smooth muscle cells involves ERK activation","volume":"279","author":"Garnovskaya","year":"2004","journal-title":"J Biol Chem"},{"issue":"43","key":"2026082903274097600_ref16","doi-asserted-by":"publisher","first-page":"35992","DOI":"10.1074\/jbc.M504583200","article-title":"Epidermal growth factor-induced rapid retinoblastoma phosphorylation at Ser780 and Ser795 is mediated by ERK1\/2 in small intestine epithelial cells","volume":"280","author":"Guo","year":"2005","journal-title":"J Biol Chem"},{"issue":"5","key":"2026082903274097600_ref17","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/BF02557826","article-title":"Human bone cells in vitro","volume":"37","author":"Robey","year":"1985","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"2026082903274097600_ref18","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/0022-1759(91)90114-u","article-title":"An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT","volume":"142","author":"Roehm","year":"1991","journal-title":"J Immunol Methods"},{"issue":"8020","key":"2026082903274097600_ref19","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41586-024-07554-2","article-title":"An intermediate Rb-E2F activity state safeguards proliferation commitment","volume":"631","author":"Konagaya","year":"2024","journal-title":"Nature."},{"issue":"5","key":"2026082903274097600_ref20","doi-asserted-by":"publisher","first-page":"R77","DOI":"10.1186\/bcr2419","article-title":"PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro","volume":"11","author":"Finn","year":"2009","journal-title":"Breast Cancer Res"},{"issue":"1","key":"2026082903274097600_ref21","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41420-024-02218-6","article-title":"CDK4\/6 inhibition initiates cell cycle arrest by nuclear translocation of RB and induces a multistep molecular response","volume":"10","author":"Hong","year":"2024","journal-title":"Cell Death Discov"},{"issue":"1","key":"2026082903274097600_ref22","doi-asserted-by":"publisher","first-page":"10","DOI":"10.18632\/oncotarget.27862","article-title":"Combination therapies for MPNSTs targeting RABL6A-RB1 signaling","volume":"12","author":"Kohlmeyer","year":"2021","journal-title":"Oncotarget."},{"issue":"1","key":"2026082903274097600_ref23","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/10781552211053639","article-title":"Tolerability of palbociclib in younger and older patients with advanced breast cancer","volume":"29","author":"Dennison","year":"2023","journal-title":"J Oncol Pharm Pract"},{"issue":"2","key":"2026082903274097600_ref24","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(20)30642-2","article-title":"Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study","volume":"22","author":"Mayer","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"2026082903274097600_ref25","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s10549-024-07312-y","article-title":"Tolerability and effectiveness of palbociclib in older women with metastatic breast cancer","volume":"206","author":"Baltussen","year":"2024","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"2026082903274097600_ref26","doi-asserted-by":"publisher","first-page":"19560","DOI":"10.1038\/s41598-023-46813-6","article-title":"Mediating oxidative stress through the Palbociclib\/miR-141-3p\/STAT4 axis in osteoporosis: a bioinformatics and experimental validation study","volume":"13","author":"Ji","year":"2023","journal-title":"Sci Rep"},{"issue":"1","key":"2026082903274097600_ref27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41413-022-00195-z","article-title":"Inhibition of Cdk5 increases osteoblast differentiation and bone mass and improves fracture healing","volume":"10","author":"Ahmad","year":"2022","journal-title":"Bone Res"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjaf186\/65883242\/zjaf186.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/41\/9\/998\/65883242\/zjaf186.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/41\/9\/998\/65883242\/zjaf186.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:27:48Z","timestamp":1787988468000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/41\/9\/998\/8380032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":27,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,12,15]]},"published-print":{"date-parts":[[2026,8,21]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmr\/zjaf186","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2025,12,15]]}}}